Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients
BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-02-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319303213 |
| _version_ | 1811330656406339584 |
|---|---|
| author | Laura Schirosi Concetta Saponaro Francesco Giotta Ondina Popescu Maria Irene Pastena Emanuela Scarpi Anita Mangia |
| author_facet | Laura Schirosi Concetta Saponaro Francesco Giotta Ondina Popescu Maria Irene Pastena Emanuela Scarpi Anita Mangia |
| author_sort | Laura Schirosi |
| collection | DOAJ |
| description | BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor infiltrating lymphocytes (TILs), Na+/H+ exchanger regulatory factor 1 (NHERF1) expression, and their association respect to the clinical outcome of patients. MATERIAL AND METHODS: NHERF1 expression was assessed by immunohistochemistry in 338 BC samples; the analysis of TILs was examined using hematoxylin and eosin stained slides, according to International TILs Working Group 2014. RESULTS: Multivariate analysis identified TILs as an independent prognostic factor for DFS in the entire cohort and in the TNBC subgroup (HR, 0.32; 95% CI, 0.12–0.87; P = 0.026; and HR, 0.22; 95% CI, 0.06–0.80; P = 0.022, respectively). Univariate and survival analysis by Kaplan–Meier method revealed that patients with cytoplasmic (c) NHERF1-/TILs+ expression had better DFS than other patients (P = 0.049), and this result was also found in the TNBC subgroup (P = 0.031). Moreover, TNBC patients with cNHERF1−/TILs− expression had a worse DFS and OS than other patients (P = 0.057 and P = 0.002, respectively). CONCLUSIONS: In the complex scenario of BC and in the era of tumor immunogenicity and immunotherapy, we found an association of TIL levels and cNHERF1 expression that could be useful to identify BCs and particularly TNBC patients with different prognosis and clinical outcome. |
| first_indexed | 2024-04-13T16:05:47Z |
| format | Article |
| id | doaj.art-8c670eb8dd754614859c734bd9b9f8eb |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-04-13T16:05:47Z |
| publishDate | 2020-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-8c670eb8dd754614859c734bd9b9f8eb2022-12-22T02:40:23ZengElsevierTranslational Oncology1936-52332020-02-01132186192Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer PatientsLaura Schirosi0Concetta Saponaro1Francesco Giotta2Ondina Popescu3Maria Irene Pastena4Emanuela Scarpi5Anita Mangia6Pathology Department, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, ItalyFunctional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, ItalyMedical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, ItalyPathology Department, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, ItalyPathology Department, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, ItalyUnit of Biostatistics and Clinical Trials, (IRST)-IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, FC 47014, ItalyFunctional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II” di Bari, 70124, Italy; Address all correspondence to: Anita Mangia, Functional Biomorphology Laboratory, IRCCS-Istituto Tumori “Giovanni Paolo II”, Bari, Italy.BACKGROUND: Breast cancer (BC) is a heterogeneous disease, and patients with apparently similar clinicopathological characteristics in clinical practice show different outcome. This study evaluated in primary BCs and in the subgroup of the triple-negative breast cancers (TNBCs) the level of tumor infiltrating lymphocytes (TILs), Na+/H+ exchanger regulatory factor 1 (NHERF1) expression, and their association respect to the clinical outcome of patients. MATERIAL AND METHODS: NHERF1 expression was assessed by immunohistochemistry in 338 BC samples; the analysis of TILs was examined using hematoxylin and eosin stained slides, according to International TILs Working Group 2014. RESULTS: Multivariate analysis identified TILs as an independent prognostic factor for DFS in the entire cohort and in the TNBC subgroup (HR, 0.32; 95% CI, 0.12–0.87; P = 0.026; and HR, 0.22; 95% CI, 0.06–0.80; P = 0.022, respectively). Univariate and survival analysis by Kaplan–Meier method revealed that patients with cytoplasmic (c) NHERF1-/TILs+ expression had better DFS than other patients (P = 0.049), and this result was also found in the TNBC subgroup (P = 0.031). Moreover, TNBC patients with cNHERF1−/TILs− expression had a worse DFS and OS than other patients (P = 0.057 and P = 0.002, respectively). CONCLUSIONS: In the complex scenario of BC and in the era of tumor immunogenicity and immunotherapy, we found an association of TIL levels and cNHERF1 expression that could be useful to identify BCs and particularly TNBC patients with different prognosis and clinical outcome.http://www.sciencedirect.com/science/article/pii/S1936523319303213 |
| spellingShingle | Laura Schirosi Concetta Saponaro Francesco Giotta Ondina Popescu Maria Irene Pastena Emanuela Scarpi Anita Mangia Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients Translational Oncology |
| title | Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients |
| title_full | Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients |
| title_fullStr | Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients |
| title_full_unstemmed | Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients |
| title_short | Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients |
| title_sort | tumor infiltrating lymphocytes and nherf1 impact on prognosis of breast cancer patients |
| url | http://www.sciencedirect.com/science/article/pii/S1936523319303213 |
| work_keys_str_mv | AT lauraschirosi tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT concettasaponaro tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT francescogiotta tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT ondinapopescu tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT mariairenepastena tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT emanuelascarpi tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients AT anitamangia tumorinfiltratinglymphocytesandnherf1impactonprognosisofbreastcancerpatients |